-
公开(公告)号：US20130164374A1
公开(公告)日：2013-06-27
申请号：US13772573
申请日：2013-02-21
申请人： J. Glenn MORRIS , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： J. Glenn MORRIS , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
IPC分类号： A61K35/76
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
-
2.发明授权公开(公告)号：US08003323B2
公开(公告)日：2011-08-23
申请号：US12264582
申请日：2008-11-04
申请人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
摘要翻译： 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。
-
3.发明申请Reduction In Bacterial Colonization By Administering Bacteriophage Compositions 审中-公开通过管理噬菌体组合物减少细菌殖民化公开(公告)号：US20120148505A1
公开(公告)日：2012-06-14
申请号：US13214579
申请日：2011-08-22
申请人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
摘要翻译： 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。
-
公开(公告)号：US06699701B1
公开(公告)日：2004-03-02
申请号：US09757687
申请日：2001-01-11
申请人： Alexander Sulakvelidze , J. Glenn Morris, Jr. , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： Alexander Sulakvelidze , J. Glenn Morris, Jr. , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
IPC分类号： C12N701
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： Methods and devices for sanitation using bacteriophage are disclosed. According to one embodiment of the present invention, a method for sanitation using at least one bacteriophage includes the steps of (1) storing the at least one bacteriophage in a container; and (2) applying the at least one bacteriophage to a surface to be sanitized with a dispersing mechanism. According to another embodiment of the present invention, a sanitation device that dispenses at least one bacteriophage includes a container, at least one bacteriophage stored in the container, and a dispersing mechanism that disperses the at least one bacteriophage from the container.
-
5.发明申请公开(公告)号：US20090053144A1
公开(公告)日：2009-02-26
申请号：US12264582
申请日：2008-11-04
申请人： J. Glenn MORRIS , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： J. Glenn MORRIS , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
摘要翻译： 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。
-
6.发明授权公开(公告)号：US07459272B2
公开(公告)日：2008-12-02
申请号：US10724900
申请日：2003-12-02
申请人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
发明人： J. Glenn Morris , Alexander Sulakvelidze , Zemphira Alavidze , Gary R. Pasternack , Torrey C. Brown
CPC分类号： C08L77/12 , A01N63/00 , A23B4/22 , A23B7/155 , A23G9/30 , A23L3/34635 , A23L3/3571 , A61K9/7007 , A61K35/76 , A61K38/164 , A61L2/00 , A61L2/0005 , A61L2/18 , A61L2/22 , A61L15/225 , A61L15/26 , A61L15/38 , A61L15/44 , A61L26/0019 , A61L26/0052 , A61L26/0066 , A61L2300/404 , C08G69/44 , C12N7/00 , C12N2795/00032 , C12N2795/00051 , Y02A50/473 , Y02A50/481
摘要： The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
摘要翻译： 本发明提供了一种通过用含有在病原菌中产生溶解性感染的一种或多种菌株的噬菌体的药物组合物治疗易感患者来降低易感患者细菌感染或败血症风险的方法。 优选地，患者的治疗通过至少一个对数降低对噬菌体敏感的致病细菌的定植水平。 在典型的实施方案中，易感患者是选自白血病患者，淋巴瘤患者，癌症患者，肉瘤患者，同种异体移植患者，先天性或后天免疫缺陷病人，囊性纤维化患者和艾滋病患者的免疫受损患者。 在优选的模式中，通过该方法治疗的患者被所述噬菌体感染的致病细菌定植。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
